Gluco- and lipotoxicity impair β cell function and survival, potentially contributing to type 2 diabetes onset and progression. Here we profiled transcriptomes of human islets in gluco/lipotoxic and type 2 diabetes conditions. Human islets from 26 nondiabetic donors were exposed to 0.5 mM palmitate (P), 22.2 mM glucose (G), P+G, 1 mM palmitate+oleate, (1:2 ratio, P+O) and P+O+G for 2 days (n=2-5/condition), followed by 4 days of washout. Glucose-stimulated insulin secretion and RNA-seq transcriptomes were assessed. Data were compared to RNA-seq of islets from 34 type 2 diabetic and 62 nondiabetic donors by rank-rank hypergeometric overlap (RRHO), and to the Connectivity Map to identify therapeutic targets. PO did not impair insulin secretion, P or G induced transient dysfunction (resolved after washout), while PG or POG induced persistent β cell dysfunction. Among common upregulated pathways in lipo- and gluco/lipotoxicity were PPAR signaling, protein processing in the endoplasmic reticulum and aminoacyl tRNA biosynthesis (gene set enrichment analysis). The greatest overlap by RRHO between upregulated genes in gluco/lipotoxicity and type 2 diabetes was seen for washout of PG and POG (conditions of persistent β cell dysfunction), with gene set enrichment for inflammatory responses and extracellular matrix organization. Comparison of gluco/lipotoxic and type 2 diabetes gene signatures with the Connectivity Map identified endoplasmic reticulum stress signaling and knockdown of the cholesterol sensor SCAP as strongly positively correlated pathways. A negative correlation was found for JNK and DNA protein kinase inhibitors, pointing to compounds that could revert gluco/lipotoxic and type 2 diabetes gene expression signatures.

In conclusion, human islet transcriptome signatures of transient or persistent gluco/lipotoxicity identify similarities to type 2 diabetes islet transcriptomes and point to novel therapeutic targets.

Disclosure

X. Yi: None. L. Marselli: None. A. Piron: None. M. Suleiman: None. D.L. Eizirik: None. P. Marchetti: Consultant; Self; Menarini Group. Research Support; Self; Janssen Pharmaceuticals, Inc. M. Cnop: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.